Table 1 Characteristics of included studies
Study | Patients, n | Male, (%) | Age, years | Intervention | Control | Follow-up |
|---|---|---|---|---|---|---|
Rosenstock et al. 2020 | 247 | 56.3 | 59.6 | Once-weekly insulin icodec | Once-daily glargine | 26 weeks |
Bajaj et al. 2021 | 104 | 72.1 | 61.7 | Once-weekly insulin icodec | Once-daily glargine | 16 weeks |
Lingvay et al. 2021 | 102 | 53.9 | 60.7 | Once-weekly insulin icodec + non-insulin glucose-lowering agents | Once-daily glargine + non-insulin glucose-lowering agents | 16 weeks |
Lingvay et al. 2023 | 588 | 62.8 | 59.0 | Once-weekly insulin icodec + non-insulin glucose-lowering agents + once-daily placebo | Once-daily degludec + non-insulin glucose-lowering agents + once-weekly placebo | 26 weeks |
Philis-Tsimikas et al. 2023 | 526 | 57.4 | 62.5 | Once-weekly insulin icodec ± non-insulin glucose-lowering agents | Once-daily degludec ± non-insulin glucose-lowering agents | 26 weeks |
Rosenstock et al. 2023 | 984 | 56.7 | 59.0 | Once-weekly insulin icodec + non-insulin glucose-lowering agents | Once-daily glargine + non-insulin glucose-lowering agents | 78 weeks |
Bue-Valleskey et al. 2023 | 278 | 54.7 | 58.4 | Once-weekly insulin Fc | Once-daily insulin degludec | 26 weeks |